Activists protest in front of the European Parliament to stop EU-India trade deal "harmful" provisions

9 April 2013

As European Commission pressure mounts on India to rush into signing a free trade agreement (FTA) by mid-April, activists from across Europe mobilized in Brussels on Tuesday (April 9) to demand the EC withdraw provisions that will harm people’s access to medicines in India and across the developing world. Civil society organizations have learnt through leaked texts that the EC, in closed-door negotiations, is aggressively pushing for stronger industry control at the expense of public health, threatening millions of lives.

Campaigners from organizations including Oxfam, Medecins Sans Frontieres (MSF), the Stop AIDS Campaign, Health Action International (HAI) Europe and Act-Up Paris protested outside the European Parliament alongside concerned MEPs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Generics